These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27473194)

  • 1. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 2. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
    Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
    Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
    [No Abstract]   [Full Text] [Related]  

  • 3. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
    Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral sciatic nerve neurolymphomatosis: PET/CT findings.
    Gorospe L; Gallego-Rivera JI; Rioja-Martín ME; Chinea-Rodríguez A
    Ann Hematol; 2017 Jun; 96(6):1059-1060. PubMed ID: 28374164
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
    Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
    Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.
    Cohen Y; Amir G; Rachmilewitz EA; Polliack A
    Haematologica; 2002 Jan; 87(1):ELT04. PubMed ID: 11801488
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):12; 14-5. PubMed ID: 24870876
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
    Yamaguchi M; Kotani T; Nakamura Y; Ueda M
    Int J Hematol; 2006 Jun; 83(5):450-3. PubMed ID: 16787878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
    Cao C; Liu T; Zhu H; Wang L; Kai S; Xiang B
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e145-50. PubMed ID: 25225082
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report and review of immunodeficiency-associated Burkitt lymphoma.
    Johnson DH; Reske T; Ruiz M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e121-5. PubMed ID: 25701328
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
    Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
    J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Di Raimondo C; Abdulla FR; Zain J; Querfeld C; Rosen ST
    Br J Haematol; 2019 Nov; 187(3):e79-e82. PubMed ID: 31566707
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
    Bolen CR; Mattiello F; Herold M; Hiddemann W; Huet S; Klapper W; Marcus R; Mir F; Salles G; Weigert O; Nielsen T; Oestergaard MZ; Venstrom JM
    Blood; 2021 May; 137(19):2704-2707. PubMed ID: 33512481
    [No Abstract]   [Full Text] [Related]  

  • 20. Bendamustine plus Rituximab versus R-miniCHOP: which is better for unfit patients with diffuse larger B-cell lymphoma?
    Zhang D; Dong Y; Zhang L
    J Chemother; 2024 Jul; 36(4):351-353. PubMed ID: 37272120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.